PE20190562A1 - Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral - Google Patents
Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoralInfo
- Publication number
- PE20190562A1 PE20190562A1 PE2018003116A PE2018003116A PE20190562A1 PE 20190562 A1 PE20190562 A1 PE 20190562A1 PE 2018003116 A PE2018003116 A PE 2018003116A PE 2018003116 A PE2018003116 A PE 2018003116A PE 20190562 A1 PE20190562 A1 PE 20190562A1
- Authority
- PE
- Peru
- Prior art keywords
- bispecific
- join
- tumor antigen
- immunomodulatory protein
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente divulgacion provee proteinas biespecificas que se unen a los antigenos CD40 y mesotelina, asi como composiciones, usos y metodos para elaborar las mismas
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342393P | 2016-05-27 | 2016-05-27 | |
US201662414897P | 2016-10-31 | 2016-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190562A1 true PE20190562A1 (es) | 2019-04-22 |
Family
ID=59067891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018003116A PE20190562A1 (es) | 2016-05-27 | 2017-05-26 | Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral |
Country Status (18)
Country | Link |
---|---|
US (2) | US20170342169A1 (es) |
EP (1) | EP3464367B1 (es) |
JP (1) | JP2019519223A (es) |
KR (1) | KR20190014525A (es) |
CN (1) | CN109476747A (es) |
AU (1) | AU2017271601A1 (es) |
BR (1) | BR112018074453A2 (es) |
CA (1) | CA3025345A1 (es) |
CL (1) | CL2018003378A1 (es) |
DO (1) | DOP2018000259A (es) |
EC (1) | ECSP18095014A (es) |
IL (1) | IL263225A (es) |
PE (1) | PE20190562A1 (es) |
PH (1) | PH12018502478A1 (es) |
RU (1) | RU2018146050A (es) |
SG (1) | SG11201810591VA (es) |
TW (1) | TW201806972A (es) |
WO (1) | WO2017205738A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201806972A (zh) * | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
SG10201914132RA (en) * | 2016-05-27 | 2020-03-30 | Abbvie Biotherapeutics Inc | Anti-cd40 antibodies and their uses |
EP3484922A1 (en) | 2016-07-14 | 2019-05-22 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
WO2018056821A1 (en) * | 2016-09-23 | 2018-03-29 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
CN113201071A (zh) * | 2017-03-28 | 2021-08-03 | 礼进生物医药科技(上海)有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
AU2018309339A1 (en) | 2017-08-04 | 2020-02-20 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
JP7311425B2 (ja) | 2017-11-08 | 2023-07-19 | 協和キリン株式会社 | CD40とEpCAMに結合するバイスペシフィック抗体 |
KR20200080304A (ko) * | 2017-11-13 | 2020-07-06 | 크레센도 바이오로직스 리미티드 | Cd137에 결합하는 단일 도메인 항체 |
CA3086098A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
EP3823992B1 (en) * | 2018-07-20 | 2023-12-13 | Duke University | Anti-lypd3 car t-cell therapy for the treatment of cancer |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
WO2020070041A1 (en) * | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-fap clone 212 |
CN112654641A (zh) * | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 具有与cd40的三价结合的双特异性抗原结合分子 |
EP3898681A2 (en) * | 2018-12-17 | 2021-10-27 | Alligator Bioscience AB | Polypeptides |
US20220064325A1 (en) * | 2018-12-17 | 2022-03-03 | Alligator Bioscience Ab | Novel polypeptides |
CN111454364B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | 结合cd40的抗体及其用途 |
EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
KR20220008820A (ko) | 2019-05-15 | 2022-01-21 | 쿄와 기린 가부시키가이샤 | Cd40과 fap에 결합하는 이중 특이적 항체 |
JPWO2020230901A1 (es) | 2019-05-15 | 2020-11-19 | ||
CN114531878A (zh) * | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
UY38995A (es) | 2019-12-20 | 2021-06-30 | Amgen Inc | Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
GB202004677D0 (en) * | 2020-03-31 | 2020-05-13 | Alligator Bioscience Ab | Methods and compositions |
JP2023530766A (ja) * | 2020-06-30 | 2023-07-19 | ハーバー・バイオメド・ユーエス・インコーポレイテッド | 二重特異性抗体及びその用途 |
JP2023535078A (ja) * | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス,インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
WO2022051591A2 (en) * | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
CN112592403B (zh) * | 2020-12-31 | 2022-04-15 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
US20240084003A1 (en) * | 2021-01-18 | 2024-03-14 | Simcere Zaiming Pharmaceutical Co., Ltd. | Anti-human cd22 monoclonal antibodies and use thereof |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
TW202321296A (zh) * | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
CN116253802A (zh) * | 2021-12-10 | 2023-06-13 | 苏州泽璟生物制药股份有限公司 | 包含lrrc15抗原结合结构域的多特异性t细胞接合剂 |
WO2023147784A1 (zh) * | 2022-02-07 | 2023-08-10 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd3的抗原结合分子及其医药用途 |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
CN114702588B (zh) * | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | 抗Nectin-4抗体和双特异性抗体 |
CN114958909A (zh) * | 2022-05-12 | 2022-08-30 | 河南晟明生物技术研究院有限公司 | 一种细胞瞬时转染的方法 |
WO2024037626A1 (zh) * | 2022-08-19 | 2024-02-22 | 盛禾(中国)生物制药有限公司 | 一种结合tnfr2和4-1bb的双特异性抗体 |
CN117327184B (zh) * | 2023-12-01 | 2024-03-05 | 赛奥斯博生物科技(北京)有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
BR0108001A (pt) | 2000-02-01 | 2004-01-06 | Tanox Inc | Moléculas ativadoras de apc com ligação para cd-40 |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
PL1707627T3 (pl) | 2003-12-25 | 2013-04-30 | Kyowa Hakko Kirin Co Ltd | Mutant antagonistycznego przeciwciała anty-CD40 |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2600505C (en) * | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
US20090074711A1 (en) | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
JP5963341B2 (ja) | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
HUE027358T2 (en) | 2007-11-26 | 2016-09-28 | Bayer Ip Gmbh | Anti-mesothelin antibodies and their applications |
JP5968624B2 (ja) | 2008-09-30 | 2016-08-10 | アッヴィ・インコーポレイテッド | 改良rnaディスプレイ法 |
EP3441404A1 (en) | 2010-09-09 | 2019-02-13 | Pfizer Inc | 4-1bb binding molecules |
SI2704737T1 (en) | 2011-04-29 | 2018-06-29 | University Of Washington | Therapeutic nucleosomal compositions and procedures |
BR112013027829B1 (pt) | 2011-04-29 | 2022-05-10 | Apexigen, Inc | Anticorpos anti-cd40 ou fragmentos de ligação aos antígenos destes, composição que compreende os ditos anticorpos e uso da dita composição para tratar ou melhorar os sintomas de câncer, doença autoimune ou doença inflamatória |
US20130171059A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2014004549A2 (en) * | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
RU2729831C2 (ru) | 2012-08-24 | 2020-08-12 | Чугаи Сейяку Кабусики Кайся | ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ |
JPWO2014065402A1 (ja) * | 2012-10-26 | 2016-09-08 | 株式会社ペルセウスプロテオミクス | 抗ヒトcd40モノクローナル抗体及びその利用 |
NZ707086A (en) | 2012-10-30 | 2019-07-26 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
US20140377253A1 (en) | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
ES2759252T3 (es) * | 2013-10-31 | 2020-05-08 | Resolve Therapeutics Llc | Fusiones y métodos terapéuticos de nucleasa-albúmina |
GB201322583D0 (en) | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
TWI726842B (zh) * | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
JP6691113B2 (ja) | 2014-10-29 | 2020-04-28 | シアトル ジェネティックス, インコーポレイテッド | 非フコシル化抗cd40抗体の投与量および投与 |
CN109195994A (zh) | 2016-04-22 | 2019-01-11 | 鳄鱼生物科学公司 | 针对cd137的新型双特异性多肽 |
TW201806972A (zh) * | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
-
2017
- 2017-05-26 TW TW106117540A patent/TW201806972A/zh unknown
- 2017-05-26 CN CN201780045719.9A patent/CN109476747A/zh active Pending
- 2017-05-26 KR KR1020187037341A patent/KR20190014525A/ko unknown
- 2017-05-26 CA CA3025345A patent/CA3025345A1/en not_active Abandoned
- 2017-05-26 US US15/606,200 patent/US20170342169A1/en not_active Abandoned
- 2017-05-26 BR BR112018074453-0A patent/BR112018074453A2/pt not_active Application Discontinuation
- 2017-05-26 PE PE2018003116A patent/PE20190562A1/es unknown
- 2017-05-26 JP JP2018561478A patent/JP2019519223A/ja active Pending
- 2017-05-26 RU RU2018146050A patent/RU2018146050A/ru not_active Application Discontinuation
- 2017-05-26 WO PCT/US2017/034675 patent/WO2017205738A1/en unknown
- 2017-05-26 EP EP17730606.5A patent/EP3464367B1/en active Active
- 2017-05-26 SG SG11201810591VA patent/SG11201810591VA/en unknown
- 2017-05-26 AU AU2017271601A patent/AU2017271601A1/en not_active Abandoned
-
2018
- 2018-02-23 US US15/903,812 patent/US10233258B2/en active Active
- 2018-11-22 IL IL263225A patent/IL263225A/en unknown
- 2018-11-23 PH PH12018502478A patent/PH12018502478A1/en unknown
- 2018-11-27 CL CL2018003378A patent/CL2018003378A1/es unknown
- 2018-11-27 DO DO2018000259A patent/DOP2018000259A/es unknown
- 2018-12-26 EC ECSENADI201895014A patent/ECSP18095014A/es unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018146050A (ru) | 2020-06-29 |
PH12018502478A1 (en) | 2019-09-23 |
CL2018003378A1 (es) | 2019-03-15 |
CA3025345A1 (en) | 2017-11-30 |
US20170342169A1 (en) | 2017-11-30 |
DOP2018000259A (es) | 2019-02-28 |
EP3464367A1 (en) | 2019-04-10 |
AU2017271601A1 (en) | 2018-12-13 |
US20180194862A1 (en) | 2018-07-12 |
IL263225A (en) | 2018-12-31 |
KR20190014525A (ko) | 2019-02-12 |
EP3464367B1 (en) | 2020-09-09 |
JP2019519223A (ja) | 2019-07-11 |
TW201806972A (zh) | 2018-03-01 |
BR112018074453A2 (pt) | 2019-03-19 |
ECSP18095014A (es) | 2019-03-29 |
US10233258B2 (en) | 2019-03-19 |
CN109476747A (zh) | 2019-03-15 |
WO2017205738A1 (en) | 2017-11-30 |
SG11201810591VA (en) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190562A1 (es) | Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral | |
GT201700112A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
CO2019003154A2 (es) | Anticuerpos anti-pd-1 y sus usos | |
CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
CL2019000061A1 (es) | Anticuerpo para anti-claudin 18a2 y su utilización. | |
GT201700131A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
CR20170511A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales. | |
SV2018005659A (es) | Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CO2018001624A2 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
CL2019001646A1 (es) | Anticuerpos anti-ox40 y sus usos. | |
CL2018002687A1 (es) | Proteínas de unión y métodos de uso de las mismas | |
CO2017001023A2 (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
BR112018004733A2 (pt) | anticorpos do receptor de transferrina humana/ a-beta anti-humana biespecíficos e métodos de uso | |
CO2018005433A2 (es) | Conjugados de fármaco de anticuerpo her2 específicos de sitio | |
PE20210648A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
CO2017005538A2 (es) | Receptores quimericos de antígeno anti–cldn | |
CR20170117A (es) | Nuevos anticuerpos anti-mf12 y métodos de uso | |
CL2017000212A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso |